December 1, 2025Journal for ImmunoTherapy of CancerOpen Access

In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses

View Full Paper

Ask AI

Bookmark

Authors

MWM Q Wang LQLi Qiu CTCheng Tang

Discussion

Member takes

Overview

Combination therapy shows improved tumor growth inhibition and robust immune response in lung and colon cancer models, indicating strong potential for cancer immunotherapy.

Key Points

Tumor growth is markedly inhibited with combined CisVac and α-CD137 treatment, showcasing enhanced immune responses.
Activating tumor antigen-specific CD8 + T cells was confirmed through single-cell RNA sequencing and antibody blockade methods.
Observational analysis across implanted mouse models suggests enhanced cell–cell communication between immune cell types.
Findings from the study indicate transformative potential of the CisVac/α-CD137 approach in addressing immune suppression.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69402a8d2d562116f2902671 https://doi.org/10.1136/jitc-2025-011665

View Full Paper

Ask AI

Bookmark

December 1, 2025Journal for ImmunoTherapy of CancerOpen Access

In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses

View Full Paper

Ask AI

Bookmark

Authors

MWM Q Wang LQLi Qiu CTCheng Tang

Discussion

Member takes

Overview

Combination therapy shows improved tumor growth inhibition and robust immune response in lung and colon cancer models, indicating strong potential for cancer immunotherapy.

Key Points

Tumor growth is markedly inhibited with combined CisVac and α-CD137 treatment, showcasing enhanced immune responses.
Activating tumor antigen-specific CD8 + T cells was confirmed through single-cell RNA sequencing and antibody blockade methods.
Observational analysis across implanted mouse models suggests enhanced cell–cell communication between immune cell types.
Findings from the study indicate transformative potential of the CisVac/α-CD137 approach in addressing immune suppression.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69402a8d2d562116f2902671 https://doi.org/10.1136/jitc-2025-011665

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark